Covetrus Names Matthew Salois President of Veterinary Study Groups (VSG)

Former Chief Economist at the AVMA to Lead Covetrus Subsidiary

PORTLAND, Maine--(BUSINESS WIRE)--Veterinary Study Groups, Inc. (VSG), a subsidiary of Covetrus^® (NASDAQ: CVET), a global leader in animal-health technology and services, has named Matt Salois, Ph.D. to the role of President of VSG. In this position, Salois will be responsible for enhancing the success of VSG, a membership organization for the owners of more than 1,800 veterinary practices.

“Matt’s experience developing and implementing strategies to assist veterinary practices in maximizing their success will be an immense asset for VSG as we help our member practices balance increasing demand for care with workforce challenges,” said Link Welborn DVM DABVP, Chief Executive Officer of VSG and Chief Veterinary Officer for Covetrus North America. “Matt’s combination of economic knowledge and veterinary industry experience is unrivaled, and his leadership will be invaluable as we work with each Veterinary Management Group (VMG) member and Covetrus to shape the future of veterinary care.”

Salois’ team of veterinarians, business leaders, event planners, and administrative professionals will work to meet the needs of each VMG member practice.

Most recently, Salois was the Chief Economist and head of the Veterinary Economics Division at the American Veterinary Medical Association (AVMA), where he enhanced the daily lives of veterinarians through his skills in economics, business, and communications. Salois also previously worked for Elanco Animal Health as the director of global scientific affairs and policy, supervising a team of scientists in veterinary medicine, human medicine, animal welfare, economics and sustainability. He is also an adjunct professor of applied economics at the University of Florida, where he previously taught and advised graduate and undergraduate students.

“Recent innovations in the veterinary industry mean we can provide better support than ever before to our partner practices, and that means better health outcomes for the animals in their care,” Salois said. “VSG’s use of data and analytics to drive decision-making combined with the comradery and community of support members receive are key to ensuring our practices can thrive, both economically and culturally. I am eager to help provide our veterinarians with the tools and the collaboration needed to enhance their practices and continue delivering exemplary health outcomes.”

Salois earned his Ph.D. in Food and Resource Economics from the University of Florida and holds an M.A. in Applied Economics and a B.S. in Health Services Administration from the University of Central Florida.

About Covetrus

Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,500 employees serving over 100,000 customers around the globe. For more information about Covetrus visit covetrus.com.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.